The Biggest HIV Stories to Follow in 2025
Jose Abrigo, Esq., HIV Project Director of the Lambda Legal Defense and Education Fund, explains the biggest HIV issues anticipated this year.
Aside from the pending FDA approval of injectable lenacapavir as a form of pre-exposure prophylaxis, Jose Abrigo, Esq., HIV Project Director of the Lambda Legal Defense and Education Fund says to expect HIV program defunding under the Trump Administration as well as updates to the Braidwood v. Becerra case, a lawsuit threatening PrEP-specific coverage requirements under the Affordable Care Act.
“The big agencies that set that help set, guide and put forward policies and furtherance of HIV prevention and HIV care, like the FDA, like the CDC, their funding is likely going to be cut,” Abrigo said in an interview with Managed Healthcare Executive.
Lenacapavir HIV PrEP: Not an AIDS Vaccine, but Vaccine Adjacent
June 19th 2025Experts and advocates say that twice-a-year HIV PrEP injections have the prevention potential of a vaccine — and that a once-a-year version of lenacapavir would be even better. But will Yeztugo be available to the people who would benefit most from HIV PrEP?
Read More
Trump Budget Axes CDC HIV Prevention, Shifts Care, Experts Warn of Risks
June 10th 2025Although some HIV programs will remain, the proposed cuts in the fiscal year 2026 budget are too severe and will hinder HIV care and research in the United States, according to Carl Schmid, executive director of the HIV+Hepatitis Policy Institute in Washington, D.C.
Read More
Most HIV Patients Trust Their Providers But Don’t Always Feel Heard, Survey Says
May 27th 2025Almost half (48%) of HIV patients sometimes feel unheard by their healthcare providers, which highlights a need for increased disease awareness, according to the early results of a new ViiV Healthcare survey.
Read More
